Furthermore, we analysed the ROC characteristics in individuals with mild cognitive impairment and mild dementia (CDR score ≤1 and MMSE >21) to investigate which tau analytes could be used to determine eligibility for Aβ-targeting therapies (A-T-: n = 18, mean age = 70, SD age = 10.6; A+T-: n = 9, mean age = 72, SD age = 6.6; A+TBraak I–IV: n = 18, mean age = 71, SD age = 9.5; A+TBraak V+: n = 34, mean age = 71, SD age = 6.1). The gene discussed is MAPT; the disease is Cognitive impairment.